Dental implants for diabetics and smokers: what the evidence says about risk, and what changes the odds

Often yes, provided the diabetes is under control. A 2022 systematic review update concluded that under controlled conditions there is no contraindication to implant surgery in people with diabetes or prediabetes, as long as appropriate precautions are followed.

The same review found that people with poorly controlled diabetes suffer peri-implantitis more often, especially after placement, and show higher implant loss in the long term (Wagner et al. 2022).

Precautions mean antibiotics and a chlorhexidine rinse around surgery, which that review calls standard because it seems to improve implant success. Only a few studies cover prediabetes, and they hint at a possible negative effect on gum and bone health around implants but no effect on survival (Wagner et al. 2022).

The largest pooled analysis is more cautious. A 2022 meta-analysis of 89 publications compared 5,510 implants in people with diabetes against 62,780 in people without. Implants in diabetic patients had higher odds of failure (odds ratio 1.777), and failures were more likely in type 1 than in type 2 diabetes (odds ratio 4.477).

The difference was significant in the upper jaw but not in the lower jaw, and bone around the implant was lost by an extra 0.776 mm on average (Al Ansari et al. 2022). An odds ratio of 1.777 means the odds of failure were roughly 1.8 times as high, not that 1.8 times as many implants failed.

Earlier meta-analyses saw little effect. A 2013 analysis of 51 studies found a clear link between failure and both smoking and radiotherapy, but no impact from diabetes, based on only 5 studies (risk ratio 0.90, not significant) (Chen et al. 2013).

A 2014 review of 14 publications also found no significant difference in failure (risk ratio 1.07), although bone loss around implants was 0.20 mm greater in diabetic patients; its authors warned that uncontrolled confounding factors limited the results (Chrcanovic et al. 2014, abstract only).

The newer analysis drew on 89 publications instead of 5 or 14, which gives it more weight. Follow-up length is one documented factor: the newer analysis estimated that the odds ratio fell by 0.007 for every additional month of follow-up (Al Ansari et al. 2022).

Another review noted it could not pool results at all, because studies differed in diabetes type, level of glucose control and duration of disease (Naujokat et al. 2016).

HbA1c is a blood test that reflects average blood sugar over the previous two to three months. One small prospective study followed 20 people with type 2 diabetes and 10 without over 4 months after placement, with HbA1c levels ranging from 4.7% to 12.6%.

Those with HbA1c of 8.1% or more had a larger drop in implant stability and needed longer for it to return to baseline (Oates et al. 2009).

Do not read 8.1% as a safe-or-unsafe line. The study was small and short. The clearest threshold in the sources used here comes from the 2025 AO/AAP consensus, which describes uncontrolled diabetes as HbA1c above 7% and says it significantly raises the risk of peri-implant inflammation and bone loss (Wang et al. 2025).

That figure is a risk marker for peri-implantitis after the implant is in place, not a rule about who may have surgery. None of the sources cited here sets an HbA1c cut-off for the surgery itself, so your surgeon and physician will use your own recent result. The same consensus rates uncontrolled diabetes as a high-risk marker for peri-implantitis.

Our guide to the surface of an implant and peri-implantitis puts that risk next to others, and peri-implantitis is explained on our gum-disease page.

Basal and compressive implants are marketed as a better fit for people with diabetes or a smoking habit, because they anchor in dense bone. The studies need a careful look. A developer-linked series of 151 patients with one-piece compressive implants included only people whose diabetes was controlled; 63 of them (41.7%) had diabetes, and survival was 100% in that group against 97.7% in the others.

The text nevertheless calls diabetes a risk factor for survival, which conflicts with that table, so the paper settles neither question (Jani et al. 2022).

A developer-linked prospective series of 87 patients reported that diabetes did not influence success, but only 5 patients (5.7%) had diabetes (Lazarov 2019).

A developer-linked 10-patient series, with 3 patients with diabetes, concluded that support from cortical bone aids their use in patients with diabetes (Patel et al. 2021).

All three series come from developer-linked teams or authors who publish with them (Jani shares an author, Pałka, with Lazarov's group, and Patel is also a developer-linked author), none of the three had a conventional-implant comparison group, and follow-up in the 151-patient series averaged about 22 months.

These series include too few people, tracked for too short a time and chosen too selectively, to show that the design removes the risk. Our review of basal implants vs conventional implants covers the wider evidence, and cortical anchorage explains the mechanism.

Smoking has a stronger and more consistent signal than diabetes. A 2021 meta-analysis of 292 publications compared 35,511 implants placed in smokers with 114,597 in non-smokers. Implants in smokers had odds of failure about 2.4 times as high (odds ratio 2.402).

The difference was significant in both the upper jaw (2.910) and lower jaw (2.866), and bone loss around the implant was 0.580 mm greater (Mustapha et al. 2021).

The 2013 analysis agrees: across 33 studies, smoking carried a risk ratio of 1.92 for implant failure (Chen et al. 2013).

The 2019 review of rough and turned surfaces names periodontitis and smoking as the two most common patient-related risk factors for biological problems (Saulacic and Schaller 2019), and the AO/AAP consensus rates current or former smoking as a high-risk marker for peri-implantitis (Wang et al. 2025).

In compressive and basal series, smoking did not predict survival: Jani had 17 smokers (11.3%) with a non-significant result (p = 0.374), and Lazarov had 26 (30.2%) with no influence reported (Jani et al. 2022; Lazarov 2019). The same caution applies as for diabetes.

Whether quitting around surgery changes the outcome is described by the 2021 meta-analysis as a question for further research, so no quitting period is quoted here. For the healing period, see implant aftercare.

The table sets the evidence next to what usually happens in planning. Planning column entries are general descriptions of the issues your team will discuss, not a protocol.

Two supports recur across the sources. Antibiotic cover and chlorhexidine are described as standard in diabetes (Wagner et al. 2022), and supportive maintenance is described as essential for long-term tissue health (Wang et al. 2025).

Treating active gum disease, including deep cleaning, usually comes first.

This checklist turns the evidence into preparation you can start now.

1. Bring your latest HbA1c result and your medication list. 2. Tell the team whether you have type 1 or type 2 diabetes. 3. Ask for help to stop smoking, and agree the timing with your surgeon. 4. Have active gum disease treated first. 5. Ask how often you will be reviewed after the bridge is fitted. 6. Ask how the bridge will be cleaned.

To see how these points apply to your case, you can request a case review.

In Dt. Yıldırım's practice, the tests asked for before surgery are HbA1c, bleeding and clotting times, fasting blood sugar, and HIV and hepatitis B and C screening. In his view this set is enough. If diabetes is not controlled, or oral care is very poor, treatment is usually postponed until control improves.

Only in exceptional cases does it go ahead, and then only after the risks are explained and written consent is taken.

He also offers a view from 25 years of practice: a flapless, low-bleeding approach, often without stitches, suits most patients whose diabetes is controlled. That is one clinician's experience, and the studies above do not test it.

On tobacco, he finds smoking and chewing tobacco a big problem. After an extraction, he advises no tobacco for 5 days. Check-ups with cleaning are advised every 6 to 24 months.

Background on the procedure is in dental implant surgery step by step, and our overview of dental implants in Turkey gives wider context.

Nexwell reads this evidence as follows. We do not treat diabetes or smoking as an automatic no, and we do not treat any implant design as a way around them. The plan should show what changes because of your risk: timing, hygiene support and review visits. A clinic that promises the same result for everyone has not looked at your history. This section is editorial framing, not a clinician's statement.

Two related guides help with the wider picture: who cannot get dental implants covers medicines and treatments, and how long dental implants last explains lifespan.

If an implant is lost, implant failure and salvage explains the options, and peri-implant care covers daily care. The idea of bone grafting is explained in bone graft for dental implants, and the biology of healing in osseointegration.

Links open the PubMed record. Chrcanovic 2014 has no open full text and is cited for its abstract only.

1. Wagner J, et al. Int J Implant Dent 2022;8(1):1. PubMed 34978649, PMC8724342.

2. Al Ansari Y, et al. Materials (Basel) 2022;15(9). PubMed 35591561, PMC9105616.

3. Chen H, et al. PLoS One 2013;8(8):e71955. PubMed 23940794, PMC3733795.

4. Chrcanovic BR, et al. J Dent Res 2014;93(9):859-867. PubMed 24928096.

5. Naujokat H, et al. Int J Implant Dent 2016;2(1):5. PubMed 27747697, PMC5005734.

6. Oates TW, et al. J Dent Res 2009;88(4):367-371. PubMed 19407159, PMC2904396.

7. Mustapha AD, et al. Medicina (Kaunas) 2021;58(1). PubMed 35056347, PMC8780868.

8. Wang HL, et al. J Periodontol 2025;96(6):519-541. PubMed 40501397, PMC12273748.

9. Saulacic N, Schaller B. J Oral Maxillofac Res 2019;10(1):e1. PubMed 31069039, PMC6498817.

10. Jani M, et al. Healthcare (Basel) 2022;10(4):598. PubMed 35455776, PMC9024819.

11. Lazarov A. Ann Maxillofac Surg 2019;9(1):78-88. PubMed 31293933, PMC6585197.

12. Patel K, et al. Ann Maxillofac Surg 2021;11(1):64-69. PubMed 34522656, PMC8407620.

This page was prepared by the Nexwell Team on 1 November 2026. Medically reviewed by Dt. Mehmet Salih Yıldırım, DDS, PhD.